Checkpoint Therapeutics announced that the U.S. Food and Drug Administration has accepted for review Checkpoint’s resubmission of its Biologics License Application, BLA, for cosibelimab, its anti-programmed death ligand-1 antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma, cSCC, who are not candidates for curative surgery or curative radiation. The resubmission has been accepted as a complete response to the FDA’s December 2023 complete response letter and the FDA has set a Prescription Drug User Fee Act, PDUFA, goal date of December 28, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CKPT:
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
- Biotech Alert: Searches spiking for these stocks today
- Checkpoint Therapeutics, GC Cell advance collaborative cancer research
- GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
- Checkpoint to sell 5.85M shares at $2.05 in registered direct offering